-
Cost-Effectiveness Analysis of Ga-PSMA-11 PET/CT Imaging Followed by Lu-PSMA-617 vs. Standard of Care in Metastatic Castrate-Resistant Prostate Cancer
Sep 9, 2025, 16:22 PM -
Treatment Preferences in Adults With Chronic Spontaneous Urticaria Symptomatic on H1-Antihistamines in China: Insights From CHOICE-CSU 2 Study
Sep 9, 2025, 16:22 PM -
How Impactful Is Time to Next Treatment on Health Technology Assessment Outcomes in Indolent Cancers?
Sep 9, 2025, 16:22 PM -
Clinical Burden and Transfusion-Related Outcomes in Transfusion-Dependent Thalassemia in the Kingdom of Saudi Arabia and United Arab Emirates
Sep 9, 2025, 16:22 PM -
Strong But Do They Ask for Help? Mental Health of Young Athletes
Sep 9, 2025, 16:22 PM -
Integrating Real-World Evidence Into Oncology HTA Submissions: Recent EU Examples
Sep 9, 2025, 16:22 PM -
Receipt of Biomarker Testing in Non-Small Cell Lung Cancer: Using Real-World Data to Identify Testing Gaps and Treatment Characteristics
Sep 9, 2025, 16:22 PM -
Treatment Patterns, Inadequate Disease Control, and Burden/Unmet Need Among Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Adelphi Real-World Disease Specific Program
Sep 9, 2025, 16:22 PM -
Confidential Prices in NICE Health Technology Assessment: How Common Are They?
Sep 9, 2025, 16:22 PM -
The Impact of Delaying Access to Innovative Therapies in Emerging Markets for Chronic Lymphocytic Leukemia: A Modeling Study
Sep 9, 2025, 16:22 PM -
Optimizing Patient Retention in Non–Site-Based Longitudinal Studies: Tailored Follow-up Strategies for Rare Disease Cohorts
Sep 9, 2025, 16:22 PM -
IMF: The Innovative Medicines Fund or the Interim Medicines Fund?
Sep 9, 2025, 16:22 PM -
Assessment of the Economic and Societal Impact of Cervical Cancer Treatment in Bulgaria
Sep 9, 2025, 16:22 PM -
Introducing the Parameter Outcome Overview Plot: A New Addition to the Sensitivity Analysis Armory for Economic Models
Sep 9, 2025, 16:22 PM -
Evolution of Manufacturer-Set List Prices and GKV Rebates for Orphan Drugs (OD) in Germany 2013-2024: How Much US WAC Is in German OD-Prices
Sep 9, 2025, 16:22 PM -
Science at PACE? A Multi-Stakeholder Developed Framework for Accelerated Patient Access to Cancer Care
Sep 9, 2025, 16:22 PM -
Integrating CEUS in Diagnostic Pathways: Evidence of Economic and Organizational Sustainability From the Italian Healthcare System
Sep 9, 2025, 16:22 PM -
Tracing the Shift in Payer Evidence Expectations: A Review of AMCP Format Updates (2016-2024)
Sep 9, 2025, 16:22 PM -
Understanding Heterogeneity in the Classification of Locally Advanced Cancer: Analysis of Clinical Trial Records From the Past 2 Years (2023-2025)
Sep 9, 2025, 16:22 PM -
Evaluating GenAI for HTA Analogue Analysis: Identifying Rare Disease Approvals With Surrogate Endpoints and Single-Arm Trials
Sep 9, 2025, 16:22 PM
